Navigation Links
A study led by CNIO validates a new anti-cancer therapy based on cell division
Date:11/18/2013

Aurora-A is a protein involved in the cell division process that is highly expressed or synthesised in a large number of human cancers, especially in those associated with a bad prognosis. Several pharmaceutical companies have recently developed these protein inhibitors, although the therapeutic and physiological effects that blocking Aurora-A might have on adult tissues are still unknown.

A study led by Ignacio Pérez de Castro, a researcher in the Spanish National Cancer Research Centre's (CNIO) Cell Division and Cancer Group, and its Group Leader, Marcos Malumbres, describes the cellular consequences of genetically deleting Aurora-A, an important target for the development of new anti-cancer agents, in mouse models. The work, which was carried out in collaboration with researchers Terry Van Dyke and Dale Cowley, from North Carolina University in the US, is published today in Cancer Research, the most cited cancer journal.

AURORA-A, AGEING AND CANCER

Aurora-A is a protein involved in the regulation of the cell cycle, a process by which cells reproduce and form tissues. Although these elementary functions had been widely studied in several model organisms and mouse embryos, their role in tissues and adult organisms remained unknown.

Using genetically engineered Aurora-A deficient mice, the authors of the study have discovered that the absence of this protein causes an increase in the number of cells with a high DNA content; this is a consequence of an aberrant distribution of the genetic material upon division.

"This phenomenon causes defects in cell proliferation, as well as an increase in the number of dead and senescent cells, which triggers premature ageing in the animals studied", says Ignacio Pérez de Castro. The researcher adds that: "In those mice, we also see an increase in DNA damage and, most importantly, a reduction in the progression of skin and breast tumours".

The study helps to solve two of the great limitations pharmaceutical companies find themselves up against when they carry out clinical trials with Aurora protein inhibitors. Firstly, the compounds used in clinical trials are not completely specific and are not capable of adequately discriminating between the three members of the Aurora family: Aurora- A, B or C. Mice generated by CNIO confirm the therapeutic value of the first member of this family of proteins.

"Secondly, clinical studies with these inhibitors have surveillance problems as a result of the lack of markers that allow monitoring their effects on the cells", says Marcos Malumbres. The researchers propose studying the volume of the cell nucleus, a consequence of a change in DNA content, as a new tool for evaluating the efficiency of these new anti-cancer drugs.

Given that Aurora-A inhibition damages DNA, Malumbres's team says that the use of Aurora-A inhibiting drugs could sensitise tumours to anti-cancer agents that are currently in clinical use and attack cells causing high levels of DNA damage.


'/>"/>

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Related medicine news :

1. Influence of pro-smoking media messages lasts 7 days, study finds
2. Study compares outcomes of device for chest compressions vs manual CPR
3. Study examines effectiveness, safety of transcatheter aortic valve replacement in US
4. New Study Reports on the High Cost of Cardiac Surgery Healthcare Associated Infections
5. Narconon Arrowhead Provides Bible Study Classes
6. Study Highlights Challenges for Individuals with Lung Cancer, Allsup Reports
7. Study unveils SINEs potential of re-activating tumor fighting proteins within a cell
8. Italian study examines clinical predictors of acute urinary symptoms after radiotherapy for prostate
9. Multicenter study underscored the need of a uniform approach to the treatment of BCa
10. Regenstrief and IU study: Older adults with severe mental illness challenge healthcare system
11. Workers’ Compensation Costs Per Claim Moderating In Pennsylvania After Years of Growth, New Study Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
Breaking Medicine Technology: